Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis

J Clin Virol. 2013 Jan;56(1):37-40. doi: 10.1016/j.jcv.2012.10.005. Epub 2012 Nov 6.

Abstract

Human parainfluenza virus (HPIV) infection as an aetiology of acute viral myocarditis is rare, with only few cases reported in the literature to date. Here we report a case of fulminant HPIV-2 myocarditis in a 47 year-old man with viraemia who was successfully treated with intravenous ribavirin and intravenous immunoglobulin (IVIG). There are currently no recommendations on the treatment of HPIV myocarditis. We are, to our knowledge, the first to report a patient with a documented HPIV-2 viraemia that subsequently cleared after the initiation of antiviral therapy. Although it is difficult to definitively attribute the patient's clinical improvement to ribavirin or IVIG alone, our case does suggest that clinicians may wish to consider initiating ribavirin and IVIG in patients with HPIV myocarditis and persistent viraemia not responding to supportive measures alone.

Publication types

  • Case Reports

MeSH terms

  • Administration, Intravenous
  • Antiviral Agents / administration & dosage*
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Myocarditis / drug therapy*
  • Myocarditis / virology
  • Parainfluenza Virus 2, Human / isolation & purification*
  • RNA, Viral / genetics
  • Ribavirin / administration & dosage*
  • Rubulavirus Infections / complications*
  • Rubulavirus Infections / drug therapy*
  • Rubulavirus Infections / virology
  • Sequence Analysis, DNA
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Immunoglobulins, Intravenous
  • RNA, Viral
  • Ribavirin

Associated data

  • GENBANK/JX889247